Life sciences briefing: Tuesday, Nov. 6, 2007
Featured companies: Ganeden Biotech, Glenveigh Medical, Lab21, Lead Therapeutics, Navigenics, Pacific Data Designs, PharMEDium Healthcare, Sloning BioTechnology, VistaGen
UPDATED: Expanded items on Lead Therapeutics, Glenveigh Medical and Sloning BioTech, and moved the Navigenics news to a separate item here.
Lead Therapeutics raises $17M for China-based work in cancer and immunology — San Bruno, Calif.-based Lead Therapeutics, a drug-development startup that plans to do most of its research and development in China, raised $17 million in a first funding round…. Continue Reading
Life sciences briefing: Friday, Aug. 10, 2007
(CORRECTED: See below.)
Featured companies: VistaGen Therapeutics, MindWeavers, Cutanea Life Sciences, Heptares Therapeutics
VistaGen raises $3.75M for stem-cell based drug discovery — South San Francisco, Calif.-based VistaGen Therapeutics, a biotech that uses human embryonic stem cells to discover new drugs, raised $3.75 million in a bridge financing as it prepares to raise up to $20 million in a fourth round, VentureWire reports (subscription required). Montaur Capital Partners provided the funding.
VistaGen, founded in 1998, isn’t your typical stem-cell company. Where… Continue Reading
VistaGen announces plans to raise up to $20M for Parkinson’s drug, but is it legal?
It is noteworthy when a company broadcasts its intentions to raise money, in part because it is legally borderline to do so.
Here is what the SEC says, regarding private securities offerings: “You may not use any form of public solicitation or general advertising in connection with the offering.” (See our post about this here, and read the helpful comment at bottom)
Yet it happens on a regular basis. Burlingame’s VistaGen Therapeutics is just the latest. Data… Continue Reading